Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysis
Our real-world data indicated that ICI-based combination therapies are effective in patients with mRCC aged ≥75 years, with outcomes largely non-inferior to non-older adult patients. However, the comparable efficacy of IO+TKI and IO+IO in the older adult group, which may differs from that in the non-older adult group, highlights the importance of understanding the distinct characteristics of each regimen for individualized treatment selection and careful management, particularly regarding AE monitoring and dose adjustment in older adult patients receiving IO+TKI.
Authors
- Takashi Nagai (ORCID: https://orcid.org/0000-0001-8116-1751)
- Yohei Tsubouchi
- Masaru Tomita (ORCID: https://orcid.org/0000-0003-3423-377X)
- Toshiharu Morikawa (ORCID: https://orcid.org/0009-0006-4430-0277)
- Taku Naiki (ORCID: https://orcid.org/0000-0002-7638-6048)
- Hisashi Ikoma (ORCID: https://orcid.org/0000-0002-2647-6854)
- Takahiro Yasui
- Takuya Sakata
- Yusuke Noda (ORCID: https://orcid.org/0000-0003-0401-6731)
- Yoshihiko Tasaki (ORCID: https://orcid.org/0000-0002-1830-7452)
- Yosuke Sugiyama (ORCID: https://orcid.org/0000-0001-8436-5872)
- Yoshihisa Mimura
- Rei Unno (ORCID: https://orcid.org/0000-0003-0584-3712)
- Hiroko Suzuki
- Masayuki Usami
- Toshiki Etani
- Shuzo Hamamoto (ORCID: https://orcid.org/0000-0002-9087-4152)
Institutions
- Nagoya City University (JP)
- Konan Kosei Hospital (JP)
- Toyota Kosei Hospital (JP)
- Anjo Kosei Hospital (JP)
- Kinan Hospital (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1668406
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00